Cancer Monoclonal Antibodies Market By Antibody Type (Murine, Chimeric, Humanized), By Application (Blood Cancer, Breast Cancer, Lung Cancer, Others), By End User (Hospitals and Clinics, Research and Academic Institute/Laboratories): Global Opportunity Analysis and Industry Forecast, 2021-2031

Cancer Monoclonal Antibodies Market

Cancer is the body's unchecked proliferation of aberrant cells. When the body's natural control system malfunctions, cancer might emerge. Instead of dying, old cells proliferate uncontrollably to produce new, aberrant cells. These excess cells could aggregate into a tissue mass known as a tumor. Leukemia is one type of cancer that does not produce tumors. Immune system proteins called monoclonal antibodies are made in laboratories. A person’s body naturally produces antibodies, which assist the immune system in identifying pathogenic microorganisms like bacteria and viruses and identifying them for eradication. Monoclonal antibodies are specific target-recognizers, just like the body's own antibodies.

Cancer is frequently treated using monoclonal antibodies. Monoclonal antibodies are within the category of targeted cancer therapy, which means that they are made to interact with targets. Some monoclonal antibodies are also used in immunotherapy because they assist the body fight cancer by activating the immune system. As an illustration, certain monoclonal antibodies label cancer cells to help the immune system more easily identify and eliminate them. As an illustration, consider the drug rituximab, which activates the immune system by binding the protein CD20 on B cells and some varieties of cancer cells. A type of white blood cell is B cells.

The market for cancer monoclonal antibody testing is expected to expand as cancer cases increase globally. For instance, according to a survey conducted by the American Cancer Society in January 2022, it is expected that every year, approximately  1.9 million new cancer cases are diagnosed and 609,360 cancer-related deaths occur in the U.S., which is about 1,670 mortality every day. Lung, prostate, bowel, and female breast cancer make up the four most prevalent cancer types worldwide, each of which accounts for 43% of all new cancer cases. Therefore, it is projected that the market for cancer monoclonal antibody testing would grow in popularity as cancer incidence rates rise internationally.

A considerable emphasis on the R&D of monoclonal antibody therapeutics to provide highly focused medication therapy for challenging and severe illnesses will increase the market growth potential for monoclonal antibodies. Government support and regulatory approvals would tremendously benefit companies looking to expand the monoclonal antibody market.

Governments all over the world have been forced to invest a significant investment in laboratories to produce extremely effective monoclonal antibodies for cancer treatment due to the surge in cancer incidence. Governments of various countries have also boosted the rate at which they approve monoclonal antibodies, which will open up a wide range of business potential in the years to come. Strategic partnerships are helping companies in the cancer monoclonal antibody testing market innovate their products more frequently. Companies are creating novel products and exchanging knowledge and expertise with other businesses in order to survive in the fiercely competitive industry. Companies have traditionally worked together with academic and research institutions in this sector through alliances and in- or out-licensing agreements, but in recent years, this trend has grown.

The cancer monoclonal antibody market is segmented on the basis of antibody type, application, end user, and region. By antibody type, the market has been divided into murine, chimeric, and humanized. By application, the market has been divided into blood cancer, breast cancer, lung cancer, and others. By end user, the market has been divided into hospitals & clinics and research & academic institutes/laboratories. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, UAE, and rest of LAMEA).

The key players profiled in this report include F. Hoffmann-La Roche Ltd., Bristol Myers, Squibb Co., Merck & Co., GlaxoSmithKline plc, Johnson & Johnson, Amgen, Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, and AbbVie. The players in the market are actively engaged in the adoption of various strategies such as acquisitions, product launches, and expansion to remain competitive and gain an advantage over competitors in the market. For instance, on December 27, 2022, ZB131 has been given the Orphan Drug designation by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer. ZB131 is a monoclonal antibody that has been developed exclusively for the highly specific and affine targeting of cancer-specific plectin (CSP). Unlike CSP, which is generally located in the cytoplasm of healthy cells, plectin has been discovered on the surface of cancer cells, where it acts as an accelerator of metastasis and tumor growth.

Key Market Insights

By antibody type, the murine sub-segment emerged as the global leader in 2021 and the humanized sub-segment is anticipated to have the fastest growth during the forecast time

By application, the blood cancer sub-segment emerged as the global leader in 2021 and the lung cancer sub-segment is anticipated to have the fastest growth during the forecast period

By end user, the hospitals & clinics segment had a dominant market share in 2021 and is predicted to show the fastest growth in the upcoming years

 Based on region, North America was the highest revenue contributor to the market in 2021, accounting for a market size of $23,023.8 million 

 

 

 

Overview

The global cancer monoclonal antibody testing market size was $55,640.00 million in 2021 and is predicted to grow with a CAGR of 7.0%, by generating a revenue of $106,825.10 million by 2031.

Monoclonal antibodies are synthetic antibodies that are directed against specific sites in the human body. On the surface of the cancer-causing cells, they serve as antigens. There are numerous monoclonal antibodies, and each one is made to solely attach to one kind of antigen. These antibodies are frequently used to treat a number of illnesses, including some forms of cancer. They deliver radioactive materials or injectable medications directly to the cancer cells. According to a study, radioactive cancer therapy is the most often used type of cancer therapy worldwide.

The increase in the geriatric population, rise in the incidence of cancer, and increase in demand for novel vaccines and therapies are some of the primary factors anticipated to drive the cancer monoclonal antibody testing market growth. The demand for effective therapies has increased owing to the rise in prevalence of different types of cancer like lung cancer, around the world, prompting researchers and scientists to accelerate their research efforts and produce effective monoclonal drugs for cancer.  These factors are projected to drive the market growth during the forecast period.

The market is significantly constrained by the high costs associated with the creation of monoclonal antibodies using cutting-edge technology. The complicated manufacturing procedure, pricey biological and chemical components, clinical trials, as well as necessary efficacy, safety, and quality tests, are the main causes of the high cost of cancer monoclonal antibody testing. Large-scale synthesis of monoclonal antibodies involving many disulfide bonds and post-translational modifications necessitates the use of expensive, specialized equipment. All these are the major factors projected to hamper the market growth during the forecast period.

Governments of various countries around the world are investing in the development of advanced cancer diagnosis and treatment methods, which is expected to boost the growth of the cancer monoclonal antibody testing market. Furthermore, many countries have established programs and initiatives aimed at providing access to cancer care for their citizens, further driving the demand for cancer monoclonal antibody tests. The increase in government support is also driving the development of new cancer monoclonal antibody tests, which are more accurate, reliable, and cost-effective. This is leading to a rise in the number of cancer patients being diagnosed at an early stage, which is increasing the demand for cancer monoclonal antibody tests. This contributes to the market rise in the cancer monoclonal antibody testing market.

The COVID-19 pandemic has had a negative impact on the cancer monoclonal antibody testing industry. During the initial phase of the pandemic, the coronavirus 2019 (COVID-19), caused significant challenges in the supply of materials, production, and logistical operations, and significantly impacted research and drug development activities. When the COVID-19 pandemic began, most businesses and research initiatives around the world suspended operations, reducing market demand for reagents and other laboratory equipment.

The key players profiled in this report include F. Hoffmann-La Roche Ltd., Bristol Myers, Squibb Co., Merck & Co., GlaxoSmithKline plc, Johnson & Johnson, Amgen, Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, and AbbVie.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer monoclonal antibodies market analysis from 2021 to 2031 to identify the prevailing cancer monoclonal antibodies market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the cancer monoclonal antibodies market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global cancer monoclonal antibodies market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Abbvie In

Scope of Cancer Monoclonal Antibodies Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.4. Market dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.5. COVID-19 Impact Analysis on the market

3.6. Key Regulation Analysis

3.7. Market Share Analysis

3.8. Patent Landscape

3.9. Regulatory Guidelines

3.10. Value Chain Analysis

4.1. Overview

4.1.1. Market size and forecast

4.2. Murine

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Chimeric

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Humanized

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Blood Cancer

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Breast Cancer

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Lung Cancer

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.5. Others

5.5.1. Key market trends, growth factors and opportunities

5.5.2. Market size and forecast, by region

5.5.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals and Clinics

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Research and Academic Institute/Laboratories

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Antibody Type

7.2.3. Market size and forecast, by Application

7.2.4. Market size and forecast, by End User

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Antibody Type

7.2.5.1.3. Market size and forecast, by Application

7.2.5.1.4. Market size and forecast, by End User

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Antibody Type

7.2.5.2.3. Market size and forecast, by Application

7.2.5.2.4. Market size and forecast, by End User

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Antibody Type

7.2.5.3.3. Market size and forecast, by Application

7.2.5.3.4. Market size and forecast, by End User

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Antibody Type

7.3.3. Market size and forecast, by Application

7.3.4. Market size and forecast, by End User

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Antibody Type

7.3.5.1.3. Market size and forecast, by Application

7.3.5.1.4. Market size and forecast, by End User

7.3.5.2. UK

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Antibody Type

7.3.5.2.3. Market size and forecast, by Application

7.3.5.2.4. Market size and forecast, by End User

7.3.5.3. France

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Antibody Type

7.3.5.3.3. Market size and forecast, by Application

7.3.5.3.4. Market size and forecast, by End User

7.3.5.4. Spain

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Antibody Type

7.3.5.4.3. Market size and forecast, by Application

7.3.5.4.4. Market size and forecast, by End User

7.3.5.5. Italy

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Antibody Type

7.3.5.5.3. Market size and forecast, by Application

7.3.5.5.4. Market size and forecast, by End User

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Antibody Type

7.3.5.6.3. Market size and forecast, by Application

7.3.5.6.4. Market size and forecast, by End User

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Antibody Type

7.4.3. Market size and forecast, by Application

7.4.4. Market size and forecast, by End User

7.4.5. Market size and forecast, by country

7.4.5.1. China

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Antibody Type

7.4.5.1.3. Market size and forecast, by Application

7.4.5.1.4. Market size and forecast, by End User

7.4.5.2. Japan

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Antibody Type

7.4.5.2.3. Market size and forecast, by Application

7.4.5.2.4. Market size and forecast, by End User

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Antibody Type

7.4.5.3.3. Market size and forecast, by Application

7.4.5.3.4. Market size and forecast, by End User

7.4.5.4. South Korea

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Antibody Type

7.4.5.4.3. Market size and forecast, by Application

7.4.5.4.4. Market size and forecast, by End User

7.4.5.5. Australia

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Antibody Type

7.4.5.5.3. Market size and forecast, by Application

7.4.5.5.4. Market size and forecast, by End User

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Antibody Type

7.4.5.6.3. Market size and forecast, by Application

7.4.5.6.4. Market size and forecast, by End User

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Antibody Type

7.5.3. Market size and forecast, by Application

7.5.4. Market size and forecast, by End User

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Antibody Type

7.5.5.1.3. Market size and forecast, by Application

7.5.5.1.4. Market size and forecast, by End User

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Antibody Type

7.5.5.2.3. Market size and forecast, by Application

7.5.5.2.4. Market size and forecast, by End User

7.5.5.3. UAE

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Antibody Type

7.5.5.3.3. Market size and forecast, by Application

7.5.5.3.4. Market size and forecast, by End User

7.5.5.4. South Africa

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Antibody Type

7.5.5.4.3. Market size and forecast, by Application

7.5.5.4.4. Market size and forecast, by End User

7.5.5.5. Rest of LAMEA

7.5.5.5.1. Key market trends, growth factors and opportunities

7.5.5.5.2. Market size and forecast, by Antibody Type

7.5.5.5.3. Market size and forecast, by Application

7.5.5.5.4. Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2021

9.1. Roche Holdings Ltd

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.2. Johnson & Johnson

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.3. Pfizer Inc.

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.4. Novartis AG

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.5. AstraZeneca plc

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.6. Merck & Co. Inc.

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.7. Celgene Limited

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.8. Bistrol-Myers Squibb

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.9. Eli Lilly & Co.

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.10. Abbvie Inc

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapsho

LIST OF TABLES

TABLE 01. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 02. CANCER MONOCLONAL ANTIBODIES MARKET FOR MURINE, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 03. CANCER MONOCLONAL ANTIBODIES MARKET FOR CHIMERIC, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 04. CANCER MONOCLONAL ANTIBODIES MARKET FOR HUMANIZED, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 05. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 06. CANCER MONOCLONAL ANTIBODIES MARKET FOR BLOOD CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 07. CANCER MONOCLONAL ANTIBODIES MARKET FOR BREAST CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 08. CANCER MONOCLONAL ANTIBODIES MARKET FOR LUNG CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 09. CANCER MONOCLONAL ANTIBODIES MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 11. CANCER MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 12. CANCER MONOCLONAL ANTIBODIES MARKET FOR RESEARCH AND ACADEMIC INSTITUTE/LABORATORIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 13. CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 14. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 15. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 16. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 17. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 18. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 19. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 20. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 21. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 22. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 23. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 24. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 25. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 26. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 27. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 28. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 29. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 30. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 31. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 32. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 33. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 34. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 35. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 36. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 37. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 38. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 39. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 40. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 41. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 42. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 43. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 44. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 45. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 46. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 47. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 48. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 49. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 50. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 51. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 52. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 53. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 54. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 55. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 56. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 57. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 58. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 59. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 60. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 61. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 62. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 63. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 64. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 65. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 66. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 67. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 68. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 69. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 70. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 71. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 72. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 73. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 74. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 75. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 76. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 77. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 78. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 79. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 80. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 81. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 82. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 83. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 84. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 85. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 86. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 87. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 88. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 89. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 90. ROCHE HOLDINGS LTD: KEY EXECUTIVES

TABLE 91. ROCHE HOLDINGS LTD: COMPANY SNAPSHOT

TABLE 92. JOHNSON & JOHNSON: KEY EXECUTIVES

TABLE 93. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 94. PFIZER INC.: KEY EXECUTIVES

TABLE 95. PFIZER INC.: COMPANY SNAPSHOT

TABLE 96. NOVARTIS AG: KEY EXECUTIVES

TABLE 97. NOVARTIS AG: COMPANY SNAPSHOT

TABLE 98. ASTRAZENECA PLC: KEY EXECUTIVES

TABLE 99. ASTRAZENECA PLC: COMPANY SNAPSHOT

TABLE 100. MERCK & CO. INC.: KEY EXECUTIVES

TABLE 101. MERCK & CO. INC.: COMPANY SNAPSHOT

TABLE 102. CELGENE LIMITED: KEY EXECUTIVES

TABLE 103. CELGENE LIMITED: COMPANY SNAPSHOT

TABLE 104. BISTROL-MYERS SQUIBB: KEY EXECUTIVES

TABLE 105. BISTROL-MYERS SQUIBB: COMPANY SNAPSHOT

TABLE 106. ELI LILLY & CO.: KEY EXECUTIVES

TABLE 107. ELI LILLY & CO.: COMPANY SNAPSHOT

TABLE 108. ABBVIE INC: KEY EXECUTIVES

TABLE 109. ABBVIE INC: COMPANY SNAPSHOT LIST OF FIGURES

FIGURE 01. CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031

FIGURE 02. SEGMENTATION OF CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031

FIGURE 03. TOP INVESTMENT POCKETS IN CANCER MONOCLONAL ANTIBODIES MARKET (2022-2031)

FIGURE 04. PORTER FIVE-1

FIGURE 05. PORTER FIVE-2

FIGURE 06. PORTER FIVE-3

FIGURE 07. PORTER FIVE-4

FIGURE 08. PORTER FIVE-5

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCANCER MONOCLONAL ANTIBODIES MARKET

FIGURE 10. IMPACT OF KEY REGULATION: CANCER MONOCLONAL ANTIBODIES MARKET

FIGURE 11. MARKET SHARE ANALYSIS: CANCER MONOCLONAL ANTIBODIES MARKET

FIGURE 12. PATENT ANALYSIS BY COMPANY

FIGURE 13. PATENT ANALYSIS BY COUNTRY

FIGURE 14. REGULATORY GUIDELINES: CANCER MONOCLONAL ANTIBODIES MARKET

FIGURE 15. VALUE CHAIN ANALYSIS: CANCER MONOCLONAL ANTIBODIES MARKET

FIGURE 16. CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR MURINE, BY COUNTRY 2021-2031(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR CHIMERIC, BY COUNTRY 2021-2031(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR HUMANIZED, BY COUNTRY 2021-2031(%)

FIGURE 20. CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR BLOOD CANCER, BY COUNTRY 2021-2031(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR BREAST CANCER, BY COUNTRY 2021-2031(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR LUNG CANCER, BY COUNTRY 2021-2031(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)

FIGURE 25. CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2021-2031(%)

FIGURE 27. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR RESEARCH AND ACADEMIC INSTITUTE/LABORATORIES, BY COUNTRY 2021-2031(%)

FIGURE 28. CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, 2021

FIGURE 29. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 30. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 31. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 32. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 33. UK CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 34. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 35. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 36. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 37. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 38. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 39. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 40. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 41. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 42. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 43. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 44. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 45. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 46. UAE CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 47. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 48. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)

FIGURE 49. TOP WINNING STRATEGIES, BY YEAR

FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 53. COMPETITIVE DASHBOARD

FIGURE 54. COMPETITIVE HEATMAP: CANCER MONOCLONAL ANTIBODIES MARKET

FIGURE 55. TOP PLAYER POSITIONING, 202